1. Home
  2. RXRX vs WLYB Comparison

RXRX vs WLYB Comparison

Compare RXRX & WLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RXRX
  • WLYB
  • Stock Information
  • Founded
  • RXRX 2013
  • WLYB 1807
  • Country
  • RXRX United States
  • WLYB United States
  • Employees
  • RXRX N/A
  • WLYB N/A
  • Industry
  • RXRX Biotechnology: Pharmaceutical Preparations
  • WLYB Books
  • Sector
  • RXRX Health Care
  • WLYB Consumer Discretionary
  • Exchange
  • RXRX Nasdaq
  • WLYB Nasdaq
  • Market Cap
  • RXRX 2.6B
  • WLYB 2.4B
  • IPO Year
  • RXRX 2021
  • WLYB N/A
  • Fundamental
  • Price
  • RXRX $9.28
  • WLYB $40.00
  • Analyst Decision
  • RXRX Buy
  • WLYB
  • Analyst Count
  • RXRX 4
  • WLYB 0
  • Target Price
  • RXRX $8.75
  • WLYB N/A
  • AVG Volume (30 Days)
  • RXRX 32.2M
  • WLYB 421.0
  • Earning Date
  • RXRX 02-28-2025
  • WLYB 03-06-2025
  • Dividend Yield
  • RXRX N/A
  • WLYB 3.54%
  • EPS Growth
  • RXRX N/A
  • WLYB N/A
  • EPS
  • RXRX N/A
  • WLYB N/A
  • Revenue
  • RXRX $65,184,000.00
  • WLYB $1,759,570,000.00
  • Revenue This Year
  • RXRX $61.89
  • WLYB N/A
  • Revenue Next Year
  • RXRX $30.83
  • WLYB $1.13
  • P/E Ratio
  • RXRX N/A
  • WLYB N/A
  • Revenue Growth
  • RXRX 37.64
  • WLYB N/A
  • 52 Week Low
  • RXRX $5.60
  • WLYB $33.01
  • 52 Week High
  • RXRX $15.74
  • WLYB $52.90
  • Technical
  • Relative Strength Index (RSI)
  • RXRX 58.05
  • WLYB 32.58
  • Support Level
  • RXRX $7.33
  • WLYB $39.89
  • Resistance Level
  • RXRX $12.36
  • WLYB $40.51
  • Average True Range (ATR)
  • RXRX 1.01
  • WLYB 0.20
  • MACD
  • RXRX 0.24
  • WLYB 0.01
  • Stochastic Oscillator
  • RXRX 43.69
  • WLYB 5.47

About RXRX Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

About WLYB John Wiley & Sons Inc.

John Wiley & Sons Inc is a provider of academic journals, books, pre- and post-hire assessments and training, test preparation materials, and online education program management solutions. The company's reportable segments are; Research, Learning, Held for Sale or Sold. The majority of the company's revenue is generated from the Research segment which provides peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. Geographically, it derives maximum revenue from the United States and the rest from the United Kingdom, China, Japan, Canada, and other countries.

Share on Social Networks: